|
Joe Amprey is a member of the Metastatix Board of Directors. He is also a Principal at MedImmune Ventures.Joseph Amprey, M.D., Ph.D., joined MedImmune Ventures, Inc. in 2006 as a principal focused on deal sourcing and portfolio management. Prior to joining MedImmune Ventures, Dr. Amprey was responsible for deal sourcing and held operational roles within the Carrot Capital (CCHV) portfolio companies. Previously, he completed an internship in internal medicine at both New York-Presbyterian Hospital and Memorial Sloan-Kettering. During medical school, he was an independent consultant to Arch Venture Partners. Dr. Amprey currently serves as a director of Synovex Corporation, Inc. and is an observer on the boards of Elusys Therapeutics, Inc. and VLST Corporation. Dr. Amprey earned both his doctorate in immunology and his medical degree from Cornell University Weill Medical College. He holds a bachelor’s degree in biochemistry from the University of Pennsylvania. He also received postgraduate training at the Brigham and Womens’ Hospital and Albert Einstein College of Medicine. | 